This finding also implies that further serum analysis of non-HCC cancer patients, especially prostate cancer patients, is clearly necessary, before the role of GOLPH2/GP73 as a serum marker specific for HCC can be further established. The gene discussed is GOLM1; the disease is prostate cancer.